Publications

Origin Trial Results as published in The New England Journal of Medicine http://www.nejm.org/doi/full/10.1056/NEJMoa1203859
http://www.nejm.org/doi/full/10.1056/NEJMoa1203858

• The ORIGIN Trial Investigators (2008). Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J; 155 (1); 26-32.
• Hanefeld M et al (2010) on behalf of the ORIGIN Trial Investigators. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med. 27 (2) 175-80.
• Badings E et al. (2011) on behalf of the ORIGIN Trial Investigators. Strategies to detect abnormal glucose metabolism in people with atherosclerotic vascular disease from the ORIGIN trial population (Outcome Reduction with Initial Glargine Intervention) Journal of Diabetes 3(3): 232-37.
• Ramachandran A et al. (2012) on behalf of the ORIGIN Trial Investigators. Relationship between Glycated Hemoglobin and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes – An Analysis of Baseline Data from the ORIGIN Trial. Diabetes Care 35(4):749-53.